Article
Gilead needs 'heroic' Immunomedics revenues to get a return on $21B deal: analyst
Rating:
0.0
Views:
62
Likes:
1
Library:
1
Gilead Sciences has long needed to diversify beyond its core antivirals business, and oncology seemed a wise choice for expansion. But should it be paying $21 billion for Immunomedics? Analysts have some doubts, at least for now.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value